Stine B. Vogensen

Stine B. Vogensen

Auto-generated profile, based on publicly available information

Stine B. Vogensen

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ULUlrike Leurs
Ulrike Leurs
AKAnders B. Klein
Anders B. Klein
EMEthan D. McSpadden
Ethan D. McSpadden
NGNane Griem-Krey
Nane Griem-Krey
SSSara Solbak
Sara Solbak
PWPetrine Wellendorph
Petrine Wellendorph
Ca2+/calmodulin-dependent protein kinase II alpha subunit (CaMKIIα) is a key neuronal signaling protein and an emerging drug target. The central hub domain regulates the activity of CaMKIIα by organizing the holoenzyme complex into functional oligomers, yet pharmacological modulation of the hub domain has never been demonstrated. Here, using a combination of photoaffinity labeling and chemical proteomics, we show that compounds related to the natural substance γ-hydroxybutyrate (GHB) bind selectively to CaMKIIα. By means of a 2.2-Å x-ray crystal structure of ligand-bound CaMKIIα hub, we reveal the molecular details of the binding site deep within the hub. Furthermore, we show that binding of GHB and related analogs to this site promotes concentration-dependent increases in hub thermal stability believed to alter holoenzyme functionality. Selectively under states of pathological CaMKIIα activation, hub ligands provide a significant and sustained neuroprotection, which is both time and dose dependent. This is demonstrated in neurons exposed to excitotoxicity and in a mouse model of cerebral ischemia with the selective GHB analog, HOCPCA (3-hydroxycyclopent-1-enecarboxylic acid). Together, our results indicate a hitherto unknown mechanism for neuroprotection by a highly specific and unforeseen interaction between the CaMKIIα hub domain and small molecule brain-penetrant GHB analogs. This establishes GHB analogs as powerful tools for investigating CaMKII neuropharmacology in general and as potential therapeutic compounds for cerebral ischemia in particular. Significance GHB is a natural brain metabolite of GABA, previously reported to be neuroprotective. However, the high-affinity binding site for GHB has remained elusive for almost 40 y. We here unveil CaMKIIα, a highly important neuronal kinase, as the long-sought-after GHB high-affinity target. Via a specific interaction within the central hub domain of CaMKIIα, GHB analogs act to stabilize the hub oligomer complex. This interaction potentially explains pronounced neuroprotective effects of GHB analogs in cultured neurons exposed to a chemical insult and in mice exposed to ischemia. The postischemic treatment effects of GHB analogs underline these compounds as selective and high-affinity potential drug candidates and CaMKIIα as a relevant pharmacological target for stroke therapy.

23 May 2014 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
AAAnas Al-Khawaja
Anas Al-Khawaja
JPJette G. Petersen
Jette G. Petersen
MDMaria Damgaard
Maria Damgaard
MJMette H. Jensen
Mette H. Jensen
SVStine B. Vogensen
Stine B. Vogensen
PWPetrine Wellendorph
Petrine Wellendorph

1 March 2004 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HVHenrik T. Vestergaard
Henrik T. Vestergaard
SVStine B. Vogensen
Stine B. Vogensen
UMUlf Madsen
Ulf Madsen
BEBjarke Ebert
Bjarke Ebert